Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
267 Results for "
candidate
" in MedChemExpress (MCE) Product Catalog:
Products (267)
267 Results for "candidate" in MCE Product Catalog:
Cat. No.: HY-110374R
CAS No.: 1992047-61-6
Research Areas:
NVS-CECR2-1 (Standard) is the analytical standard of NVS-CECR2-1 (HY-110374). This product is intended for research and analytical applications. NVS-CECR2-1, a non-BET family Bromodomain (BRD) inhibitor, is a potent and selective cat eye syndrome chromosome region, candidate 2 (CECR2) inhibitor. NVS-CECR2-1 binds to CECR2 BRD with high affinity (IC50=47 nM; Kd=80 nM). NVS-CECR2-1 exhibits cytotoxic activity and induces apoptosis against various cancer cells by targeting CECR2 as well as via CECR2-independent mechanism . NVS-CECR2-1 is a chemical probe.
Cat. No.: HY-118243
CAS No.: 1089681-42-4
KMS88009 is a potent small molecule that directly interferes with the formation of amyloid-β oligomers, thereby preserving cognitive behavior when used preventively and reversing cognitive behavior decline when used therapeutically. Oral administration of KMS88009 around the onset of Alzheimer's disease symptoms significantly reduced the assembly of amyloid-β oligomers and improved cognitive behavior in the APP/PS1 double transgenic mouse model. This unique dual mode of action suggests that KMS88009 may be a powerful therapeutic candidate for the treatment of Alzheimer's disease. In an evaluation, the physicochemical properties, pharmacokinetics and toxicity of this anti-amyloidogenic small molecule KMS88009 were studied, as well as post-mortem analysis of APP/PS1 TG mice after behavioral testing.
Cat. No.: HY-170958
Scr-IN-1 (Compound 4e) is a Tyrosine kinase inhibitor. Scr-IN-1 inhibits HCT-116 cells and MIA-PaCa-2 cells with IC50s of 0.16 μM and 1.16 μM, respectively. Scr-IN-1 displays selectivity profile on HCT-116 cells and MIA-PaCa-2 cells with SI > 625 and SI > 86, respectively. Scr-IN-1 induces Apoptosis in HCT-116 colon cancer cell and does not cause any change in the rate of necrotic cells. Scr-IN-1 is a novel SRC kinase inhibitor candidate for HCT-116 cells. Scr-IN-1 is potential for cancer research .
Cat. No.: HY-B1692R
CAS No.: 15985-39-4
Synonyms: MSX (Standard); MSO (Standard)
Target:
Research Areas:
L-Methionine-DL-sulfoximine (Standard) is the analytical standard of L-Methionine-DL-sulfoximine (HY-B1692). This product is intended for research and analytical applications. L-Methionine-DL-sulfoximine (MSX; MSO), a highly specific and irreversible inhibitor of Glutamine synthetase (GS), is also a potent convulsant which metabolically and morphologically primarily affects astroglia. L-Methionine-DL-sulfoximine has been employed to inhibit the Gln-dependent ammonia-stimulated neuronal toxicity in vitro, potentiating Gln deficit-dependent depression. L-Methionine-DL-sulfoximine tremendously increases the rate of release of fixed nitrogen in cyanobacteria. L-Methionine-DL-sulfoximine is a promising candidate for research in biofertilizers and convulsive seizures (CS) .
Cat. No.: HY-W133953
CAS No.: 108-65-6
Synonyms: Propylene glycol monomethyl ether acetate
Target:
Research Areas:
1-Methoxy-2-propyl acetate is a volatile ester compound found in chocolate made from fermented cocoa beans. 1-Methoxy-2-propyl acetate serves as a hydrolysis substrate for esterases in blood, liver, lung, and nasal mucosa, and is rapidly hydrolyzed to propylene glycol monomethyl ether and acetic acid. 1-Methoxy-2-propyl acetate is proposed as a candidate urinary biomarker for dairy product intake. 1-Methoxy-2-propyl acetate can serve as a solvent and is applied in the electronic-grade semiconductor industry. 1-Methoxy-2-propyl acetate can be used in research related to nephropathy, hepatomegaly, and nasal irritation .
Cat. No.: HY-L0120V
170,269 compounds
“BioDesign” approach incorporates key structural features of known pharmacologically relevant natural products (e.g. alkaloids and other secondary metabolites) into synthetically feasible medicinal chemistry scaffolds. In order to identify the privileged pharmacophores, ring systems and linkers, we have carried out statistical analysis of structural features of natural products, marketed drugs, and drug candidates.
Saturated, fused ring, spiro, and bridged systems with a tendency towards multiple chiral centers are highly privileged among natural products and marketed drugs yet these structures are very poorly represented in commercial libraries. This library addressed this market need by incorporating these privileged elements into the design of novel synthetic molecules with high molecular framework diversity, multiple stereogenic centers (≥2), and degree of saturation (Fsp3 > 0.5).
Cat. No.: HY-L061
5,513 compounds
Most of the drugs that are available in the marketplace are administered via the oral route, which is a convenient and cost effective route of administration. Thus, oral bioavailability is one of the key considerations in drug design and development. A high oral bioavailability reduces the amount of an administered drug necessary to achieve a desired pharmacological effect and therefore could reduce the risk of side-effects and toxicity. A poor oral bioavailability can result in low efficacy and higher inter-individual variability and therefore can lead to unpredictable response to a drug. Low oral bioavailability in clinical trials is a major reason for drug candidates failing to reach the market.
MCE offers a unique collection of 5,513 compounds with confirmed high oral bioavailability. MCE Orally Active Compound Library is a useful tool for discovering new drugs with oral bioavailability.
Cat. No.: HY-P74798
Purity: ≥ 85%, as determined by reducing SDS-PAGE.
Synonyms: ING4; CDNA FLJ53613, Highly Similar To Inhibitor Of Growth Protein 4; Inhibitor Of Growth Family Member 4; Inhibitor Of Growth Family Member 4 Variant DeltaEx6B; P29ING4; candidate Tumor Suppressor P33 ING1 Homolog; My036; Brain My036 Protein; Inhibitor O
Species:
Human
Source:
E. coli
Cat. No.: HY-P701362
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: CDK15; Serine/Threonine-Protein Kinase PFTAIRE-2; Prev. ALS2CR7; Cell Division Protein Kinase 15; Prev. PFTK2; Cyclin-Dependent Kinase 15; PFTAIRE2; PFTAIRE Protein Kinase 2; Amyotrophic Lateral Sclerosis 2 Chromosomal Region candidate Gene 7 Protein; Ser
Species:
Human
Source:
Sf9 insect cells
Cat. No.: HY-P702695
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: CDK15; Serine/Threonine-Protein Kinase PFTAIRE-2; Prev. ALS2CR7; Cell Division Protein Kinase 15; Prev. PFTK2; Cyclin-Dependent Kinase 15; PFTAIRE2; PFTAIRE Protein Kinase 2; Amyotrophic Lateral Sclerosis 2 Chromosomal Region candidate Gene 7 Protein; Ser
Species:
Human
Source:
Sf9 insect cells
Cat. No.: HY-P87320
Synonyms: Adapt 78 antibody; Adapt78 antibody; Calcipressin 1 antibody; Calcipressin-1 antibody; Calcium and oxidant inducible mRNA antibody; CSP 1 antibody; CSP1 antibody; Down syndrome candidate region 1 antibody; Down syndrome critical region gene 1 antibody; Down syndrome critical region protein 1 antibody
Cat. No.: HY-145973B
Research Areas:
3'OMe-m7GpppAmpG (Tris) is a trinucleotide Cap1 analog with the structure m7 (3'OMeG)(5') ppp (5')(2'OMeA) pG, and also functions as a cis-acting ligase ribozyme inhibitor. 3'OMe-m7GpppAmpG (Tris) effectively reduces free 5'-triphosphate groups on RNA transcripts, thereby enabling efficient co-transcriptional capping of in vitro transcribed mRNA. 3'OMe-m7GpppAmpG (Tris) is not only widely used in the preparation of modified mRNA including trivalent influenza vaccine candidates, but also applicable to studies related to SARS-CoV-2 infection and other relevant research .
Cat. No.: HY-145973
CAS No.: 2089461-55-0
Synonyms: m7(3'OMeG)(5')ppp(5')(2'OMeA)pG
Research Areas:
3’OMe-m7GpppAmpG (m7(3'OMeG)(5')ppp(5')(2'OMeA)pG) is a trinucleotide Cap1 analog with the structure m7 (3'OMeG)(5') ppp (5')(2'OMeA) pG, and also functions as a cis-acting ligase ribozyme inhibitor. 3’OMe-m7GpppAmpG effectively reduces free 5'-triphosphate groups on RNA transcripts, thereby enabling efficient co-transcriptional capping of in vitro transcribed mRNA. 3’OMe-m7GpppAmpG is not only widely used in the preparation of modified mRNA including trivalent influenza vaccine candidates, but also applicable to studies related to SARS-CoV-2 infection and other relevant research .
Cat. No.: HY-14977
CAS No.: 840523-39-9
Target:
Research Areas:
CS-0777-P, the phosphorylated form of CS-0777, acts as a potent and selective modulator of the S1P receptor-1 (S1P1). It exhibits approximately 320-fold higher agonist activity for human S1P1 compared to S1P3, with an EC50 of 1.1 nM. In pharmacological studies, CS-0777-P demonstrated significant effects in vitro as an S1P1 and S1P3 agonist, leading to lowered peripheral blood lymphocyte counts and suppressive effects on experimental autoimmune encephalomyelitis (EAE) in rats. Pharmacokinetic studies in rats revealed rapid lymphocyte count reductions following oral administration, making CS-0777 a promising candidate currently undergoing clinical trials for the treatment of multiple sclerosis (MS) .
Research Areas:
16-Epiestriol (16-epi-Estriol; 16β,17β-Estriol) is a natural stereoisomer of estriol and an anti-inflammatory agent that targets UGT. The Ki values of 16-Epiestriol against human UGT1A10 and UGT2B7 are 98.1 μM and 162 μM, respectively. As a glucuronidation substrate, 16-Epiestriol can be modified at the 3-OH, 16-OH and 17-OH sites by various UGT enzymes; in liver microsomes, the modification mainly occurs at the 16-OH and 17-OH sites, while reactions take place at all three sites in intestinal microsomes. 16-Epiestriol acts on the phase II inflammatory process by blocking edema mediated by prostaglandins and leukocyte infiltration. It lacks glycogenic activity or any effect on blood glucose levels, and serves as an important candidate molecule in the research of inflammatory diseases .
Cat. No.: HY-145973A
Purity: ≥99.0%
Synonyms: m7(3'OMeG)(5')ppp(5')(2'OMeA)pG ammonium solution (100 mM)
Cat. No.: HY-111297
CAS No.: 868843-84-9
Target:
Research Areas:
BMVC4 is a G-quadruplex (G4) stabilizer of the human telomeric sequence d[AG3(T2AG3)3]. Screening by circular dichroism (CD) spectroscopy revealed that BMVC4 is more suitable as the core molecule of G4 stabilizers than BMVC. The results showed that BMVC4-12C and BMVC4-8C3O are better candidates for G4 stabilizers and are worthy of further study. A simple and rapid screening method based on Cu2+-induced G4 unfolding can be used to find better G4 stabilizers for potential anticancer applications. CD results showed that the trivalent cations of 9-substituted BMVC derivatives are more suitable as G4 stabilizers than the divalent cations of BMVC. In addition, by monitoring the disappearance of the 291 nm CD band of human telomeres after Cu2+ addition, it was found that the core molecule of G4 stabilizer BMVC4 has better stability.
Cat. No.: HY-130046R
CAS No.: 547-81-9
Synonyms: 16-epi-Estriol (Standard); 16β,17β-Estriol (Standard)
Research Areas:
16-Epiestriol (Standard) is the analytical standard of 16-Epiestriol (HY-130046). This product is intended for research and analytical applications. 16-Epiestriol (16-epi-Estriol; 16β,17β-Estriol) is a natural stereoisomer of estriol and an anti-inflammatory agent that targets UGT. The Ki values of 16-Epiestriol against human UGT1A10 and UGT2B7 are 98.1 μM and 162 μM, respectively. As a glucuronidation substrate, 16-Epiestriol can be modified at the 3-OH, 16-OH and 17-OH sites by various UGT enzymes; in liver microsomes, the modification mainly occurs at the 16-OH and 17-OH sites, while reactions take place at all three sites in intestinal microsomes. 16-Epiestriol acts on the phase II inflammatory process by blocking edema mediated by prostaglandins and leukocyte infiltration. It lacks glycogenic activity or any effect on blood glucose levels, and serves as an important candidate molecule in the research of inflammatory diseases .
Cat. No.: HY-175862
CAS No.: 2135481-84-2
Target:
Free Radical Scavengers Aldose Reductase Reactive Oxygen Species (ROS) PI3K Akt SOD p38 MAPK Keap1-Nrf2
Research Areas:
ALR2-IN-9 is a potent ALR2 inhibitor (IC50 = 21.8 nM) with excellent antioxidant activity (EC50 for DPPH radical scavenging = 2.8 μM). ALR2-IN-9 interacts directly with Reactive Oxygen Species (ROS)/Reactive Nitrogen Species (RNS) and interrupts the free radical chain reactions, and as an endogenous enzymatic antioxidant regulator, which regulates enzyme functions of CAT and SOD. ALR2-IN-9 regulates PI3K/Akt/Nrf2 pathway to attenuate hyperglycemia-mediated mitochondrial superoxide overproduction in vitro, and ameliorates CuSO4- and H2O2-induced oxidative stress in vivo. ALR2-IN-9 prolongs lifespan of C. elegans via the regulation of stress response genes such as PMK-1. ALR2-IN-9 is a promising anti-aging drug candidate. ALR2-IN-9 can be used for diabetic complication research .
Cat. No.: HY-164729
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
